In vitro study of gut microbiota-mediated response to Salmonella Typhimurium with a focus on dynamics and immune modulation
4 affiliations
- 1Department of Food Science & Technology, Chungnam National University, Daejeon, South Korea
- 2Department of Food and Nutrition, Gyeongsang National University, Jinju, South Korea
- 3Department of Biotechnology, The Catholic University of Korea, Bucheon, South Korea
- 4Department of Bio and Medical Bigdata (BK4 Program), Gyeongsang National University, Jinju, South Korea
Abstract
Salmonella enterica serovar Typhimurium is a major foodborne pathogen that disrupts gut microbial balance and induces intestinal inflammation. Microbial analysis revealed that S. Typhimurium infection increased the abundance of short-chain fatty acid (SCFA)-producing bacteria, including Bacteroides, Parabacteroides, and members of the Clostridia group, while decreasing Escherichia-Shigella in an in vitro fecal fermentation model. Co‑culture experiments demonstrated that gut microbiota inhibited S. Typhimurium growth and host cell interactions while attenuating cytotoxicity and inflammatory responses (IL‑1β, IL‑6, and c‑Jun) in Caco-2 cells in a dose‑dependent manner. Interestingly, gut microbiota improved epithelial cell viability, indicating barrier‑protective and immunomodulatory functions. These findings demonstrate that human gut microbiota plays a crucial role in mitigating the pathogenicity of S. Typhimurium and maintaining intestinal homeostasis, supporting the potential of microbiota‑based strategies for infection control.
Related
- Reduced efficacy of food-chain biocides and preservatives against ciprofloxacin-resistant Salmonella Typhimurium.
- Microbiota-mediated modulation of the tumor microenvironment in urological cancers: crosstalk between gut and intratumoral microbiota
- Modular design of Salmonella Typhimurium OMV-based nanovaccines for tunable dual-form polysaccharide antigen delivery
- Subverting colonization resistance: Salmonella pathogenesis at the interface of microbiota, metabolism and inflammasome.
- Gut microbiota modulation of gastrointestinal cancers: from dysbiosis signatures to therapeutic interventions
BibTeX
@article{kim2026vitro,
title = {{In vitro study of gut microbiota-mediated response to Salmonella Typhimurium with a focus on dynamics and immune modulation}},
author = {Dong Woo Kim and Saloni Singh and Hyeon Ji Je and Jun Hong Shin and Ui in Kim and Dong Young Lee and Eun Ju Yun and Seung Ho Shin and Ok Kyung Koo},
journal = {Virulence},
year = {2026},
month = nov,
doi = {10.1080/21505594.2026.2758464},
url = {https://doi.org/10.1080/21505594.2026.2758464},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - In vitro study of gut microbiota-mediated response to Salmonella Typhimurium with a focus on dynamics and immune modulation
AU - Dong Woo Kim
AU - Saloni Singh
AU - Hyeon Ji Je
AU - Jun Hong Shin
AU - Ui in Kim
AU - Dong Young Lee
AU - Eun Ju Yun
AU - Seung Ho Shin
AU - Ok Kyung Koo
PY - 2026
DA - 2026/11/05
JO - Virulence
DO - 10.1080/21505594.2026.2758464
UR - https://doi.org/10.1080/21505594.2026.2758464
AB - Salmonella enterica serovar Typhimurium is a major foodborne pathogen that disrupts gut microbial balance and induces intestinal inflammation. Microbial analysis revealed that S. Typhimurium infection increased the abundance of short-chain fatty acid (SCFA)-producing bacteria, including Bacteroides, Parabacteroides, and members of the Clostridia group, while decreasing Escherichia-Shigella in an in vitro fecal fermentation model. Co‑culture experiments demonstrated that gut microbiota inhibited S. Typhimurium growth and host cell interactions while attenuating cytotoxicity and inflammatory responses (IL‑1β, IL‑6, and c‑Jun) in Caco-2 cells in a dose‑dependent manner. Interestingly, gut microbiota improved epithelial cell viability, indicating barrier‑protective and immunomodulatory functions. These findings demonstrate that human gut microbiota plays a crucial role in mitigating the pathogenicity of S. Typhimurium and maintaining intestinal homeostasis, supporting the potential of microbiota‑based strategies for infection control.
SN - 2150-5594
SN - 2150-5608
ER -